Spectral MD Holdings, Ltd
("Spectral MD" or the "Company")
Block Listing Six Monthly Return
LONDON, U.K. AND DALLAS, TX, U.S -Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, provides the following information in connection with its block admissions pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies:
| Name of applicant: | Spectral MD Holdings, Ltd. | |||
| Name of scheme: | 2018 Long-Term Incentive Plan | |||
| Period of return: | From: | 8 November 2022 | To: | 7 May 2023 |
| Balance of unallotted securities under scheme(s) from previous return: | 2,000,000 Ordinary shares | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | - | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | 104,451 Ordinary shares | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,895,549 Ordinary shares | |||
| | | | | |
| Name of contact: | Vince Capone, General Counsel/Corporate Secretary |
| Telephone number of contact: | +1 972 499-4934 |
For further information please contact:
| Spectral MD Holdings, Ltd. |
| |
| Wensheng Fan, Chief Executive Officer Nils Windler, Chief Financial Officer | IR@Spectralmd.com via Walbrook PR | |
|
|
| |
| SP Angel Corporate Finance LLP (NOMAD and Joint Broker for Spectral MD) |
| |
| Stuart Gledhill / Harry Davies-Ball (Corporate Finance) Vadim Alexandre / Rob Rees (Sales & Broking) | Tel: +44 (0)20 3470 0470
| |
|
|
| |
| The Equity Group Inc. (US Investor Relations) |
| |
| Devin Sullivan | dsullivan@equityny.com Tel: 212-836-9608 | |
|
|
| |
| Walbrook PR Ltd (UK Media & Investor Relations) |
| |
| Paul McManus / Louis Ashe-Jepson /Alice Woodings | spectralMD@walbrookpr.com Tel: +44 (0)20 7933 8780 | |
About Spectral MD
Spectral MD is a predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care for burn, DFU, and future clinical applications. At Spectral MD, we are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown"® with our DeepView® Wound Diagnostics System. The Company's DeepView® platform is the only predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results that substantially exceed the current standard of care, Spectral MD's diagnostic platform is expected to provide faster and more accurate treatment insight, significantly improving patient care and clinical outcomes. For more information, visit the Company at: www.spectralmd.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.